Skip to content

Nasal dexmedetomidine and oral chloral hydrate during electroencephalogram

Comparative study of the effect of nasal dexmedetomidine and oral chloral hydrate on pediatric sedation during electroencephalogram

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210614051574N8
Enrollment
64
Registered
2022-02-15
Start date
2022-03-05
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electroencephalogram. Abnormal electroencephalogram [EEG]

Interventions

Intervention 1: Intervention group 1: Patients in this group, before the intervention, recieve intranasal dexmedetomidine from Abu Reihan company with dosage of 2-3 micrograms per kilogram and 10 minu

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Months to 6 Years

Inclusion criteria

Inclusion criteria: Children 6 months to 6 years Candidate for electroencephalogram for any reason Lack of proper cooperation to perform electroencephalogram Need to create sedation for electroencephalogram

Exclusion criteria

Exclusion criteria: History of respiratory diseases, peptic ulcer, liver disease Existence of treatment with drugs that interact with chloral hydrate or dexmedetomidine Lack of written informed consent of parents for children to enter the study

Design outcomes

Primary

MeasureTime frame
Heart rate. Timepoint: Before the start of the process and during the process at intervals of every 5 minutes. Method of measurement: Cardiac monitoring device.;Blood pressure. Timepoint: Before the start of the process and during the process at intervals of every 5 minutes. Method of measurement: Cardiac monitoring device.;Sleep onset latency. Timepoint: Before the start of the process and during the process at intervals of every 5 minutes. Method of measurement: Cardiac monitoring device.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadreza Ghazavi

Esfahan University of Medical Sciences

mohammadsharifi.ghasem@gmail.com+98 31 3729 4005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026